HGH Fragment 176-191 2mg Research Peptide
HGH Fragment 176-191 is a synthetic peptide corresponding to amino acids 176–191 of the C-terminal region of human growth hormone. This fragment retains the lipolytic (fat-mobilizing) activity of full-length HGH while lacking the growth-promoting and insulin-desensitizing effects associated with the full molecule. It acts by mimicking the way growth hormone regulates fat metabolism through a mechanism independent of IGF-1 signaling, making it a selective research tool for studying adipose tissue metabolism without the confounding systemic anabolic effects of full GH. This 2mg vial provides research-grade HGH Fragment 176-191 at ≥99% purity, HPLC and MS/MS verified per batch.
Research Background
Originally isolated and studied by researchers at Monash University (Australia), HGH Fragment 176-191 demonstrated selective lipolytic activity in adipocytes while showing no mitogenic or diabetogenic effects in preclinical models — a key finding that distinguished it from full-length GH for metabolic research. Rodent studies demonstrated significant reductions in body fat, particularly visceral adipose tissue, without the insulin resistance seen with exogenous GH administration. It stimulates lipolysis and inhibits lipogenesis in adipocyte models through beta-3 adrenergic receptor-mediated pathways.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 2mg per vial
- Storage: −20°C, protected from light
- Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
- Molecular Weight: 1817.1 Da
Certificate of Analysis
All HGH Fragment 176-191 vials are third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
